Pemvidutide (ALT-801) is Altimmune's investigational balanced 1:1 GLP-1 and glucagon receptor dual-agonist peptide. The glucagon receptor arm drives direct hepatic effects — reductions in liver fat, inflammation, and fibrosis — while the GLP-1 arm produces appetite suppression and weight loss. The combined mechanism positions pemvidutide as a candidate first-line therapy for MASH (metabolic dysfunction-associated steatohepatitis), the indication where Altimmune holds FDA Fast Track plus Breakthrough Therapy Designation.
The Phase 2b IMPACT trial randomized 212 biopsy-confirmed MASH patients (F2-F3 fibrosis, with and without diabetes) to weekly subcutaneous pemvidutide 1.2 mg, 1.8 mg, or placebo over 48 weeks. The 48-week analysis was selected as 'Best of EASL 2026,' the meeting's top-tier curated designation. EASL 2026 Day 1 (May 27 Barcelona) brought the late-breaking poster LBP-036 with HistoIndex qFibrosis-measured fibrosis regression at 24 weeks plus concurrent improvements across multiple non-invasive tests of liver inflammation and fibrosis. The Thursday May 28 oral presentation at 17:00 CEST anchors the full 48-week efficacy and safety data.
Stories here cover pemvidutide trial readouts, the broader Altimmune pipeline including alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) indications, and the competitive MASH-peptide landscape. See #altimmune, #mash, and #glp-1-glucagon for adjacent threads.
EASL 2026 wraps in Barcelona Saturday May 30 after a week that confirmed MASH as a multi-mechanism therapeutic battleground. The GLP-1/glucagon peptide cohort delivered the headline data: Boehringer Ingelheim's survodutide full 48-week Phase 2 results in the NEJM (47-62% MASH improvement without fibrosis worsening, Phase 3 LIVERAGE enrolling); Altimmune's pemvidutide 48-week IMPACT data selected 'Best of EASL 2026' (triglycerides -23.7%, weight -7.5%, with HistoIndex qFibrosis fibrosis regression); MetaVia DA-1726 higher-dose Phase 1. The non-peptide cohort: Madrigal Rezdiffra eight-poster cardiovascular and portal-hypertension data, Aligos ALG-055009 THR-β (46.2% liver fat), Arrowhead ARO-INHBE RNAi (44% liver fat plus tirzepatide combination doubling weight loss), Galectin belapectin, Sagimet denifanstat. Novo Nordisk's ESSENCE Japanese and menopausal subgroups plus real-world burden data anchored the semaglutide MASH-labeling case. The week established that no single mechanism dominates MASH — GLP-1/glucagon leads on combined weight-plus-liver effect, THR-β and FGF21 lead on direct antifibrotic action, and combination therapy is the emerging 2027-2028 thesis.
Altimmune presented the full Week 48 top-line IMPACT Phase 2b oral data for pemvidutide in MASH today at EASL 2026 Barcelona (Dr. Mazen Noureddin, Houston Methodist Hospital, 17:00 CEST). The 1.8 mg dose reduced triglycerides 23.7%, total cholesterol 15.4%, body weight 7.5%, BMI 3.0 kg/m², and waist circumference 5.3 cm, alongside blood pressure reduction. Safety held at 48 weeks with roughly 1% discontinuation due to adverse events and mostly mild-to-moderate gastrointestinal events. Previously reported: 27.8% (1.2 mg) and 32.4% (1.8 mg) of patients achieved combined ELF and LSM improvements versus 3.2% on placebo. The 48-week analysis carries the 'Best of EASL 2026' designation. Pemvidutide is a balanced 1:1 GLP-1/glucagon dual receptor agonist peptide with FDA Fast Track + Breakthrough Therapy Designations for MASH. The cardiometabolic-risk-factor profile positions pemvidutide as differentiated on the lipid and cardiovascular axis versus pure GLP-1 agonists.
Altimmune released new analyses from the IMPACT Phase 2b trial today at EASL 2026 Barcelona. The late-breaking poster LBP-036 (Dr. Shaheen Tomah, 08:30 CEST) reported pemvidutide treatment produced concurrent improvements across multiple non-invasive tests of MASH activity and fibrosis, with HistoIndex qFibrosis digital-pathology analysis documenting significant fibrosis-stage improvements at 24 weeks versus placebo. The trial randomized 212 biopsy-confirmed MASH patients (F2-F3 fibrosis, with and without diabetes) to weekly subcutaneous pemvidutide 1.2 mg, 1.8 mg, or placebo over 48 weeks. Companion data on response analysis across NITs of liver inflammation/fibrosis and cardiovascular measures landed in additional posters. The abstract carries the EASL committee's 'Best of EASL 2026' top-tier selection. Pemvidutide is a 1:1 balanced GLP-1/glucagon dual receptor agonist peptide with FDA Fast Track + Breakthrough Therapy Designations for MASH; oral presentation Thursday May 28 at 17:00 CEST anchors the 48-week efficacy and safety data.
EASL 2026 Day 1 in Barcelona delivered the most concentrated MASH-therapeutics data cycle of 2026. The peptide-mechanism cohort: Altimmune pemvidutide qFibrosis fibrosis regression (LBP-036), MetaVia DA-1726 48 mg Phase 1 noninvasive liver assessment, Novo Nordisk ESSENCE Japanese/menopausal subgroups. The non-peptide-mechanism cohort: Arrowhead ARO-INHBE RNAi (Activin E/ALK7 pathway), Galectin Therapeutics belapectin NAVIGATE (galectin-3 inhibitor), Sagimet Biosciences denifanstat + resmetirom combination (FASN inhibitor + Madrigal's Rezdiffra), Madrigal eight-poster Rezdiffra data drop on cardiovascular and portal hypertension markers. The combined cycle reframes MASH as a multi-mechanism battleground rather than a single-class indication — GLP-1/glucagon peptides compete against thyroid-hormone-receptor agonism, RNAi, galectin-3 inhibition, FASN inhibition, and emerging combinations. Thursday May 28 brings the Altimmune pemvidutide oral presentation at 17:00 CEST; Friday May 29 brings ASCO opening in Chicago to anchor the parallel peptide-oncology cycle.
Altimmune confirmed the IMPACT Phase 2b 48-week analysis on pemvidutide in MASH was selected as a 'Best of EASL 2026' abstract — the highest-tier curated designation at the European Association for the Study of the Liver Congress. The oral presentation is scheduled Thursday May 28 at 17:00 CEST in Barcelona, complementing the late-breaking fibrosis-regression poster Wednesday May 27 08:30 CEST. The 'Best of EASL' selection elevates pemvidutide relative to the broader MASH-peptide slate at the meeting (Novo Nordisk's ESSENCE semaglutide liver safety, Boehringer Ingelheim's survodutide SYNCHRONIZE-1 forward-look, Madrigal's Rezdiffra portal hypertension data) and is the meeting committee's editorial signal that the IMPACT Phase 2b data set is among the highest-impact contributions to the congress.
Altimmune presents IMPACT Phase 2b clinical trial data on pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the Liver Congress 2026 (May 27-30 Barcelona). The randomized, placebo-controlled, double-blind Phase 2b trial enrolled 212 biopsy-confirmed MASH patients with fibrosis stages F2 or F3 (with and without diabetes), randomized 1:2:2 to weekly subcutaneous pemvidutide 1.2 mg, 1.8 mg, or placebo for 48 weeks. The late-breaking poster Wednesday May 27 at 08:30 CEST reports the AI-based Liver Explore quantitative digital pathology analysis showing significant reductions in proportionate areas of early, advanced, and total liver fibrosis at 24 weeks. The non-invasive PRO-C3:CTX-III ratio reduced consistent with fibrosis regression. Pemvidutide is a GLP-1/glucagon dual-action peptide with FDA Fast Track designation for MASH plus Breakthrough Therapy Designation. The approach competes directly with Boehringer Ingelheim's survodutide and Eli Lilly's retatrutide on the GLP-1/glucagon arm for MASH.